Animal model studies and anecdotal case reports suggest that high dose therapy supported by allogeneic stem cell transplantation may lead to the remission in some autoimmune diseases (ADs). Autologous transplantation has also been successful in some cases. Allogeneic bone marrow transplantation is presently not an acceptable option for the majority of patients with severe autoimmnune diseases because of its high transplant related mortality estimated at about 15-30%. During the last few years more than 180 Autologous Stem Cell Transplantation (ASCT) have been reported to the EULAR-EBMT data base. Early data suggest some clinical benefit for the majority of patients although a longer follow up is needed to define the duration of remission. Moreover unexpected complication were described in some patients undergoing this procedure so that transplant related mortality in ASCT for ADs is estimated at about 5-10%. The use of ASCT in the treatment of severe ADs is only at the beginning and, missing prospective comparative studies, it's impossible to judge whether this form of intensive treatment may have some role in the therapy of these diseases.
|Translated title of the contribution||Haematopoietic stem cell transplantation (HSCT) for autoimmune diseases (ADS)|
|Number of pages||11|
|Publication status||Published - 2000|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health